Patents by Inventor Brian Lanman

Brian Lanman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • S1P Receptor Modulating Compounds and Use Thereof
    Publication number: 20120088749
    Abstract: The present invention relates to amides that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
    Type: Application
    Filed: December 16, 2011
    Publication date: April 12, 2012
    Applicants: EPIX PHARMACEUTICALS, INC., AMGEN, INC.
    Inventors: Susana C. Neira, Xiang Yu, Roland Burli, Victor Cee, Brian Lanman
  • S1P receptor modulating compounds and use thereof
    Patent number: 8080542
    Abstract: The present invention relates to amides that have activity as SIP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: December 20, 2011
    Assignees: Amgen, Inc., Epix Pharmaceuticals, Inc.
    Inventors: Susana C. Neira, Xiang Yu, Roland Burli, Victor Cee, Brian Lanman
  • S1P receptor modulating compounds and use thereof
    Publication number: 20080027036
    Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
    Type: Application
    Filed: March 21, 2007
    Publication date: January 31, 2008
    Applicant: EPIX Delaware, Inc.
    Inventors: Roland Burli, Victor Cee, Jennifer Golden, Brian Lanman, Susana Neira, Ashis Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa Cheruku, Pini Orbach, Anurag Sharadendu, Robert Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker, Zhaoda Zhang
  • Saframycins, analogues and uses thereof
    Publication number: 20070112008
    Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof. In another aspect, the present invention provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. In yet another aspect, the present invention provides methods for treating cancer comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof.
    Type: Application
    Filed: October 17, 2006
    Publication date: May 17, 2007
    Inventors: Andrew Myers, Alleyn Plowright, Daniel Kung, Brian Lanman
  • Saframycins, analogues and uses thereof
    Patent number: 6809099
    Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof. In another aspect, the present invention provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. In yet another aspect, the present invention provides methods for treating cancer comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: October 26, 2004
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Alleyn T. Plowright, Daniel W. Kung, Brian Lanman
  • Saframycins, analogues and uses thereof
    Publication number: 20030008873
    Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof.
    Type: Application
    Filed: November 5, 2001
    Publication date: January 9, 2003
    Inventors: Andrew G Myers, Alleyn T. Plowright, Daniel W. Kung, Brian Lanman